PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology... Show more
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PYPD declined for three days, in of 308 cases, the price declined further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for PYPD moved out of overbought territory on June 17, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator moved out of overbought territory. In of the 9 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 44 cases where PYPD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
PYPD broke above its upper Bollinger Band on June 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on June 02, 2025. You may want to consider a long position or call options on PYPD as a result. In of 120 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PYPD just turned positive on June 02, 2025. Looking at past instances where PYPD's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
PYPD moved above its 50-day moving average on May 29, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PYPD advanced for three days, in of 192 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 55 cases where PYPD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PYPD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PYPD's P/B Ratio (434.783) is very high in comparison to the industry average of (16.460). P/E Ratio (0.000) is within average values for comparable stocks, (58.911). PYPD's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.291). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.526).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PYPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes
Industry Biotechnology
A.I.dvisor indicates that over the last year, PYPD has been loosely correlated with VTYX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if PYPD jumps, then VTYX could also see price increases.
Ticker / NAME | Correlation To PYPD | 1D Price Change % | ||
---|---|---|---|---|
PYPD | 100% | +12.20% | ||
VTYX - PYPD | 37% Loosely correlated | +6.19% | ||
AMLX - PYPD | 29% Poorly correlated | -0.59% | ||
MESO - PYPD | 29% Poorly correlated | -2.64% | ||
INM - PYPD | 28% Poorly correlated | -1.61% | ||
VRAX - PYPD | 28% Poorly correlated | -4.27% | ||
More |